Among patients who underwent percutaneous coronary intervention (PCI) with third-generation drug-eluting stents (DES), net adverse clinical events (NACE) were similar between patients who were prescribed a shorter duration of dual antiplatelet therapy (DAPT; 3 to 6 months) or standard DAPT (12 months), a new study shows.